EMEA-003537-PIP01-23

EMEA-003528-PIP01-23

Opinion/decision on a Paediatric investigation plan (PIP): Piqray, Alpelisib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Congenital, familial and genetic disorders, PIP number: P/0090/2024

Human medicines European public assessment report (EPAR): Zyprexa, olanzapine, Date of authorisation: 27/09/1996, Revision: 46, Status: Authorised

Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) annual activity report 2024

On-boarding of users to Substance, Product, Organisation and Referentials (SPOR) data services

Opinion/decision on a Paediatric investigation plan (PIP): Aspaveli, Pegcetacoplan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: P/0099/2024

Opinion/decision on a Paediatric investigation plan (PIP): Supemtek Tetra (previously Supemtek), recombinant Influenza Hemagglutinin-strain A (H1N1 subtype),recombinant Influenza Hemagglutinin-strain A (H3N2 subtype),recombinant Influenza Hemagglutinin-strain B (Victoria lineage),recombinant Influenza Hemagglutinin-strain B (Yamagata lineage) (RIV4), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: P/0098/2024

EMEA-003220-PIP01-22-M01

EMEA-003215-PIP01-22-M01